Tenax Therapeutics Faces Legal Scrutiny After Trial Failure

The clinical trial, designed to evaluate the efficacy of TNX-103 in treating PH-HFpEF, produced results that disappointed investors. Data revealed only a 3.5-meter placebo-adjusted improvement in the six-minute walk distance—a figure deemed statistically insignificant—and showed no measurable impact on the Kansas City Cardiomyopathy Questionnaire symptom scores. This outcome starkly contrasted with the company's earlier guidance, which had aimed for a successful topline readout by August 2026.

Levi & Korsinsky is now evaluating potential securities law violations related to the price drop. The firm notes that eligibility for the investigation extends to both current shareholders and those who sold their positions at a loss following the disclosure. Participation carries no upfront costs, as the firm operates on a contingency basis, and does not require investors to attend court or provide testimony. Interested parties are encouraged to provide brokerage records detailing purchase dates and share quantities to determine eligibility for recovery.